Decision-Making in Cancer Research

October 2016 Vol 7, No 9


Clinical Research
Barbara Biedrzycki, PhD, CRNP, AOCNP

Background: Cancer clinical research is essential to producing evidence-based clinical care that offers better treatment outcomes. Yet the recruiting and consenting process for cancer clinical trials can be challenging and lead to slow-accruing clinical research and dissatisfaction. Respect for autonomy and fear of unduly influencing the research participation decision may hinder our involvement with the decision-making process. A conceptual model of the research decision-making process would be helpful to identify the factors associated with research decision-making and to generate future research.

Objectives: Describe the factors associated with research decision-making. Define decision-making preferences. Discuss the Research Decision-Making Model.

Methods: Cross-sectional, descriptive research of mailed surveys to 197 patients with advanced gastrointestinal cancer who were invited to participate in a treatment-based cancer clinical trial. Prior to receiving the surveys, potential research participants were invited to participate by a mailed introductory letter along with an opt-out return postcard. If the postcard was not received in 2 weeks, the surveys and stamped return envelope were mailed. If surveys were not received within 2 weeks, a second mailing was sent with a return postcard that provided the options to decline research participation or request a second set of surveys and stamped envelope. Each mailing reminded participants of the voluntary nature of research and that the surveys do not need to be completed at one time. Research participants were sent a $20 gift card and hand-written thank you note on receipt of surveys. This study was IRB approved.

Results: Response rate was 46%, guided by the Dillman Method for survey research. Statistical analysis of age, gender, cancer diagnosis, and cancer stage indicated no statistical difference between survey responders and those 54% who did not respond. Through logistic regression analysis, all 13 variables of the Research Decision-Making Model (cancer stage, symptom burden, age, educational level, race, sex, hope, quality of life, trust in healthcare system, trust in healthcare professional, preference for research decision control, perceived risks and benefits, and adequacy of research information) together predicted cancer clinical trial participation (P = .032) and satisfaction with the research decision (P = .007). Individual predictors were age for clinical trial participation (P = .009); and hope (P = .019) and trust in the healthcare system (P = .003) for decision satisfaction. Most research participants (163/197; 83%) preferred shared (also known as collaborative) decision-making.

Conclusions: Research decision-making is a multifactorial process conceptualized and validated by the Research Decision-Making Model. Shared decision-making preference is an unrecognized factor for cancer clinical research decision-making. Patient and nurse navigators’ awareness of the many factors impacting the decision-making process and the patient’s decision-making preference may facilitate optimal navigation within clinical research. Interventional research is needed to determine the impact of decision-making support on clinical trial accrual, satisfaction, and quality of life, and to further test the Research Decision-Making Model.

Related Articles
Upper Gastrointestinal (GI) Morbidity and Gastric Acid–Reducing Agent (GARA) Use Among Oncolytic-Treated Patients with Non-Hodgkin Lymphomas: Nursing Perspective Insights
November 2022 Vol 13, No 11
To evaluate the epidemiology of upper GI morbidity, peptic ulcer risk, and prescription GARA use among patients with MCL or CLL/SLL and provide the nursing perspective on GARA use in oncology patient care.
Patient-Reported Outcomes from the Phase 3, Randomized Study of Acalabrutinib with or without Obinutuzumab versus Chlorambucil plus Obinutuzumab for Treatment-Naive Chronic Lymphocytic Leukemia (ELEVATE-TN)
P Walker , JP Sharman, W Jurczak, T Munir, V Banerji, S Coutre, JA Woyach, G Salles, WG Wierda, P Patel, MH Wang, U Emeribe, E Flood, JC Byrd, P Ghia
December 2021 Vol 12, No 12
Nursing Experience in Patients with Chronic Lymphocytic Leukemia Receiving First-Line Ibrutinib: Up to 7 Years of Follow-Up from the Phase 3 RESONATE-2 Study
Cara McGowan, NP, Jillian Settlemire, RN, Anita Szoke, MD, Gabriel Krigsfeld, PhD, Steven Coutre, MD, Paul Barr, MD
December 2021 Vol 12, No 12
Last modified: August 10, 2023

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
    Profession or Role
    Primary Specialty or Disease State